These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 26558729)

  • 1. Incidence of malaria by cotrimoxazole use in HIV-infected Ugandan adults on antiretroviral therapy: a randomised, placebo-controlled study.
    Kasirye RP; Baisley K; Munderi P; Levin J; Anywaine Z; Nunn A; Kamali A; Grosskurth H
    AIDS; 2016 Feb; 30(4):635-44. PubMed ID: 26558729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal effect of CD4 by cotrimoxazole use on malaria incidence among HIV-infected Ugandan adults on antiretroviral therapy: a randomized controlled study.
    Kasirye R; Grosskurth H; Munderi P; Levin J; Anywaine Z; Nunn A; Kamali A; Baisley K
    Malar J; 2016 Jul; 15():361. PubMed ID: 27417903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of antiretroviral therapy on malaria incidence in HIV-infected Ugandan adults.
    Kasirye RP; Grosskurth H; Munderi P; Levin J; Anywaine Z; Nunn A; Kamali A; Baisley K
    AIDS; 2017 Feb; 31(4):577-582. PubMed ID: 28121670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of discontinuing cotrimoxazole prophylaxis among HIV infected adults on anti-retroviral therapy in Uganda (COSTOP trial): Design.
    Anywaine Z; Abaasa A; Levin J; Kasirye R; Kamali A; Grosskurth H; Munderi P; Nunn A
    Contemp Clin Trials; 2015 Jul; 43():100-4. PubMed ID: 26009024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Malaria Parasitemia and Parasite Density in Antiretroviral-Treated HIV-Infected Adults Following Discontinuation of Cotrimoxazole Prophylaxis.
    Ottichilo RK; Polyak CS; Guyah B; Singa B; Nyataya J; Yuhas K; John-Stewart G; Waitumbi JN
    J Infect Dis; 2017 Jan; 215(1):88-94. PubMed ID: 28077587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cotrimoxazole Prophylaxis Discontinuation among Antiretroviral-Treated HIV-1-Infected Adults in Kenya: A Randomized Non-inferiority Trial.
    Polyak CS; Yuhas K; Singa B; Khaemba M; Walson J; Richardson BA; John-Stewart G
    PLoS Med; 2016 Jan; 13(1):e1001934. PubMed ID: 26731191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discontinuing cotrimoxazole preventive therapy in HIV-infected adults who are stable on antiretroviral treatment in Uganda (COSTOP): A randomised placebo controlled trial.
    Anywaine Z; Levin J; Kasirye R; Lutaakome JK; Abaasa A; Nunn A; Grosskurth H; Munderi P;
    PLoS One; 2018; 13(12):e0206907. PubMed ID: 30596666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of cotrimoxazole prophylaxis on malaria occurrence among HIV-infected adults in West Africa: the MALHIV Study.
    Eholié SP; Ello FN; Coffie PA; Héma A; Minta DK; Sawadogo A
    Trop Med Int Health; 2017 Sep; 22(9):1186-1195. PubMed ID: 28653454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of co-trimoxazole prophylaxis, antiretroviral therapy, and insecticide-treated bednets on the frequency of malaria in HIV-1-infected adults in Uganda: a prospective cohort study.
    Mermin J; Ekwaru JP; Liechty CA; Were W; Downing R; Ransom R; Weidle P; Lule J; Coutinho A; Solberg P
    Lancet; 2006 Apr; 367(9518):1256-61. PubMed ID: 16631881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-infected ugandan adults taking antiretroviral therapy with CD4 counts >200 cells/μL who discontinue cotrimoxazole prophylaxis have increased risk of malaria and diarrhea.
    Campbell JD; Moore D; Degerman R; Kaharuza F; Were W; Muramuzi E; Odongo G; Wetaka M; Mermin J; Tappero JW
    Clin Infect Dis; 2012 Apr; 54(8):1204-11. PubMed ID: 22423133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased malaria parasitaemia among adults living with HIV who have discontinued cotrimoxazole prophylaxis in Kitgum district, Uganda.
    Orishaba P; Kalyango JN; Byakika-Kibwika P; Arinaitwe E; Wandera B; Katairo T; Muzeyi W; Nansikombi HT; Nakato A; Mutabazi T; Kamya MR; Dorsey G; Nankabirwa JI
    PLoS One; 2020; 15(11):e0240838. PubMed ID: 33175844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of HIV and malaria parasites co-infection on immune-hematological profiles among patients attending anti-retroviral treatment (ART) clinic in Infectious Disease Hospital Kano, Nigeria.
    Jegede FE; Oyeyi TI; Abdulrahman SA; Mbah HA; Badru T; Agbakwuru C; Adedokun O
    PLoS One; 2017; 12(3):e0174233. PubMed ID: 28346490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of cotrimoxazole prophylaxis on the incidence of malaria in HIV-infected children in 2012, in Abidjan, Côte d'Ivoire: a prospective cohort study.
    Harouna AM; Amorissani-Folquet M; Eboua FT; Desmonde S; N'Gbeche S; Aka EA; Kouadio K; Kouacou B; Malateste K; Bosse-Amani C; Ahuatchi Coffie P; Leroy V;
    BMC Infect Dis; 2015 Aug; 15():317. PubMed ID: 26248711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized trial of prolonged co-trimoxazole in HIV-infected children in Africa.
    Bwakura-Dangarembizi M; Kendall L; Bakeera-Kitaka S; Nahirya-Ntege P; Keishanyu R; Nathoo K; Spyer MJ; Kekitiinwa A; Lutaakome J; Mhute T; Kasirye P; Munderi P; Musiime V; Gibb DM; Walker AS; Prendergast AJ
    N Engl J Med; 2014 Jan; 370(1):41-53. PubMed ID: 24382064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Marked reduction in prevalence of malaria parasitemia and anemia in HIV-infected pregnant women taking cotrimoxazole with or without sulfadoxine-pyrimethamine intermittent preventive therapy during pregnancy in Malawi.
    Kapito-Tembo A; Meshnick SR; van Hensbroek MB; Phiri K; Fitzgerald M; Mwapasa V
    J Infect Dis; 2011 Feb; 203(4):464-72. PubMed ID: 21216867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cotrimoxazole prophylaxis versus mefloquine intermittent preventive treatment to prevent malaria in HIV-infected pregnant women: two randomized controlled trials.
    Denoeud-Ndam L; Zannou DM; Fourcade C; Taron-Brocard C; Porcher R; Atadokpede F; Komongui DG; Dossou-Gbete L; Afangnihoun A; Ndam NT; Girard PM; Cot M
    J Acquir Immune Defic Syndr; 2014 Feb; 65(2):198-206. PubMed ID: 24220287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High burden of malaria among Malawian adults on antiretroviral therapy after discontinuing prophylaxis.
    Mungwira RG; Laurens MB; Nyangulu W; Divala TH; Nampota-Nkomba N; Buchwald AG; Nyirenda OM; Mwinjiwa E; Kanjala M; Galileya LT; Earland DE; Adams M; Plowe CV; Taylor TE; Mallewa J; van Oosterhout JJ; Laufer MK;
    AIDS; 2022 Oct; 36(12):1675-1682. PubMed ID: 35848575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective efficacy of co-trimoxazole prophylaxis against malaria in HIV exposed children in rural Uganda: a randomised clinical trial.
    Sandison TG; Homsy J; Arinaitwe E; Wanzira H; Kakuru A; Bigira V; Kalamya J; Vora N; Kublin J; Kamya MR; Dorsey G; Tappero JW
    BMJ; 2011 Mar; 342():d1617. PubMed ID: 21454456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved growth and anemia in HIV-infected African children taking cotrimoxazole prophylaxis.
    Prendergast A; Walker AS; Mulenga V; Chintu C; Gibb DM
    Clin Infect Dis; 2011 Apr; 52(7):953-6. PubMed ID: 21427404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.